NFSG
GTBP icon

Newbridge Financial Services Group’s GT Biopharma GTBP Stock Holding History

Newbridge Financial Services Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53K Hold
3,750
– – ﹤0.01% 1048
2025
Q4 		$2.94K Hold
3,750
– – ﹤0.01% 979
2025
Q3 		$2.2K Buy
3,750
+1,000
+36% +$1.49K ﹤0.01% 1125
2025
Q2 		$9.85K Buy
2,750
+1,000
+57% +$2.58K ﹤0.01% 892
2025
Q1 		$3.76K Hold
1,750
– – ﹤0.01% 835
2024
Q4 		$5.34K Buy
+1,750
New +$4.73K ﹤0.01% 851

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Newbridge Financial Services Group's GTBP Position: Q1 2026 in Review

Newbridge Financial Services Group held its GT Biopharma (GTBP) position steady in Q1 2026 at 3,750 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1048.

Newbridge Financial Services Group first reported a position in GTBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.85K in Q2 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Newbridge Financial Services Group held 3,750 shares of GT Biopharma worth $1.53K as of Q1 2026.
  • Newbridge Financial Services Group left its GT Biopharma share count unchanged in Q1 2026.
  • GT Biopharma made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1048 holding.
  • Newbridge Financial Services Group first reported a position in GT Biopharma in Q4 2024 and has held it in 6 quarters since.
  • Newbridge Financial Services Group's GT Biopharma position peaked at $9.85K in Q2 2025.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.